[Immunotherapy of severe gram-negative bacterial infections. Centoxin: a new drug under monitoring. National Committee for the Evaluation of Centoxin].
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D016470:Bacteremia / Q000382:microbiology / Q000628:therapy*; D004341:Drug Evaluation; D004731:Endotoxins / Q000627:therapeutic use*; D016905:Gram-Negative Bacterial Infections / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D008991:Monitoring, Physiologic
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004731:Endotoxins; C068069:nebacumab
Immunothérapie des infections graves à bacilles à gram négatif. Le centoxin: un médicament en liberté surveillée. Comité National d'Evaluation du Centoxin.